First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 millionRaises ...
TG Therapeutics recently reported its first-quarter 2026 results, with revenue rising to US$204.92 million and net income reaching US$19.78 million, and raised its full-year 2026 total global revenue ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Why TG Therapeutics (TGTX) is back on many investors’ radar TG Therapeutics (TGTX) has drawn fresh attention after recent share price moves, with returns of 27% over the past week and about 49% over ...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. TG Therapeutics (TGTX) has been drawing attention after recent trading moves, with the stock ...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. TG Therapeutics's (NYSE:TGTX) short percent of float has fallen 12.86% since its last report. The company recently reported that it has 31.83 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results